___

• Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
• Süt N, Şenocak M. Relatif Risk Ölçütünün Odds Oranı, Atfedilen Risk ve Tedaviye Gerekli Sayı Ölçütleriyle Karşılaştırılması. Trakya Univ Tip Fak Derg 2007;24:213-221
• Möller HJ, Fountoulakis KN. Problems in determining efficacy and effectiveness of antidepressants. Psychiatrike. 2011 Oct- Dec;22:298-306.
• Srivastava S, Ketter TA.Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther. 2011;33:40-8.
• Kok RM, Heeren TJ, Nolen WA.Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double- blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry. 2011;19:249-55.
• Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol. 2011;14:261-8.
• Van Lieshout RJ, MacQueen GM.Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. Br J Psychiatry. 2010;196:266-73.
• Alvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first- episode psychosis. Schizophr Bull. 2011;37:619-30.
• Watanabe N, Furukawa TA, Shimodera S, Morokuma I, Katsuki F, Fujita H, Sasaki M, Kawamura C, Perlis ML. Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. J Clin Psychiatry. 2011;72:1651-8.
• Jayaram M, Rattehalli RD, Kader I.Prompt letters to reduce non- attendance: applying evidence based practice. BMC Psychiatry. 2008;16:8:90.
• Mössler K, Chen X, Heldal TO, Gold C. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev. 2011;7:CD004025.
• Wongpakaran T, Petcharaj K, Wongpakaran N, Sombatmai S, Boripuntakul T, Intarakamhaeng D, Wannarit K. The effect of telephone-based intervention (TBI) in alcohol abusers: a pilot study. J Med Assoc Thai. 2011;94:849-56.
• Roozen HG, de Waart R, van der Kroft. P. Community reinforcement and family training: an effective option to engage treatment- resistant substance-abusing individuals in treatment. Addiction. 2010;105:1729-38. doi: 10.1111/j.1360-0443.2010.03016.x.
• Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS One. 2010;13:13196.
• Smith EG, Sİndergård L, Lopez AG, Andersen PK, Kessing LV.Association between consistent purchase of anticonvulsants or lithium and suicide risk: a longitudinal cohort study from Denmark, 1995-2001.J Affect Disord. 2009;117:162-7.
• Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR.A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69:302-9.
• Correll CU, Kishimoto T, Nielsen J, Kane JM.Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33:B16-39.
• Citrome L. Relative vs. absolute measures of benefit and risk: what’s the difference? Acta Psychiatr Scand. 2010;121:94-102. Epub 2009 Aug 19.
• Richard T, Vanhaeverbeek M, Van Meerhaeghe A. The number needed to treat (NNT). Rev Med Brux. 2011;32:453-8.
• Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122:39-48.
• Correll CU, Sheridan EM, DelBello MP.Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12:116-41.
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63:1762-84. Epub 2009 Oct 14.
• Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev. 2009;8:CD005146.
• Srivastava S, Ketter TA. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther. 2011;33:B40-8.
• Ketter TA, Citrome L, Wang PW, Culver JL, Srivastava S. Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions? Acta Psychiatr Scand. 2011;123:175-89. doi: 10.1111/j.1600-0447.2010.01645.x. Epub 2010 Dec 7.
• Popovic D, Reinares M, Amann B, Salamero M, Vieta E.Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl). 2011;213:657-67.
• Stewart JA, Deliyannides DA, Hellerstein DJ, McGrath PJ, Stewart JW.Can people with nonsevere major depression benefit from antidepressant medication? J Clin Psychiatry. 2011 Dec 27. [Epub ahead of print]
• Gopal S, Berwaerts J, Nuamah I, Akhras K, Coppola D, Daly E, Hough D, Palumbo J.Number needed to treat and number needed to harm with paliperidone palmitate relative to long- acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr Dis Treat. 2011;7:93-101.